Surgery of Primary Breast Cancer

Fisher, Bernard

doi:10.1007/978-1-4757-0480-8_1

Cited by 5 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along with steroid receptors, other prognostic variables have been reported: no dal status [31], thymidine labeling index [32,33], percentage of S phase [34], and more recently the amplification of the neu onco gene [35], All these studies stress the need for the identification of markers of tumor agressiveness in breast disease in order to accu rately define groups with poor prognosis who might need more intensive adjuvant treat ment. The experimental evidence from cell culture studies supports such a role for growth factors and their receptor.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Estimation of Epidermal Growth Factor Receptors and Steroid Receptors in a Series of 136 Resectable Primary Breast Tumors

et al. 1988

View full text Add to dashboard Cite

Human breast cancer cell lines, as well as human breast cancer biopsies, possess specific high-affinity epidermal growth factor receptors (EGF-r). However, reports on the presence of EGF-r in human breast cancer biopsies are still controversial, especially concerning the relationship between EGF-r and other biological variables whose prognostic relevance is well known, such as the estrogen (ER) and progesterone (PgR) receptors. In the present study, the EGF-r content was estimated in a series of 136 unselected breast cancer primaries along with cytoplasmic (ERc) and nuclear (ERn) ER and cytoplasmic PgR. EGF-binding activity consisted of a single class of high-affinity binding sites (K_d = 0.55 nM) and ranged from 0 to 275 fmol/mg protein. We observed a strong inverse association between EGF-r and ERc (p < 0.001); in fact, about two thirds of the tumors were ERc-positive/EGF-r-negative or ERc-negative/EGF-r-positive. The same type of association was found between EGF-r and either ERn or PgR.Kendall’s rank correlation test confirmed that the EGF-r concentrations were correlated with the levels of ERc (τ = -0.291, p < 0.0001), ERn (τ = -0.27, p < 0.0005) and PgR (τ = -0.162, p < 0.01). The EGF-r content was significantly higher (p < 0.0001) in the ERc-negative tumors (72.6 ± 54.4 fmol/mg protein) as compared to the ERc-positive ones (33.0 ± 37.4 fmol/mg protein). Similarly, the subset of PgR-positive tumors was characterized by lower EGF-r mean concentrations when compared to PgR-negative cases (35.4 ± 54.4 vs. 63.8 ± 54.4 fmol/mg protein). These results confirm the previously described inverse relationship between EGF-r and steroid receptors. Moreover, they suggest the existence of an interaction between steroid hormones and EGF and support the need for further studies to better understand their respective roles in modulating breast cancer growth.

show abstract

Section: Discussionmentioning

confidence: 99%

Simultaneous Estimation of Epidermal Growth Factor Receptors and Steroid Receptors in a Series of 136 Resectable Primary Breast Tumors

et al. 1988

View full text Add to dashboard Cite

show abstract

“…This author for more than a decade has repeatedly reviewed in detail those laboratory and clinical investigations which have given rise to a hypothesis alternative to that upon which the primary management of solid tumors has been based for almost 100 years (1)(2)(3)(4)(5). Findings have also been reported which supply additional support to, and confirmation of, the validity of various components of the alternative hypothesis (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

A commentary on the role of the surgeon in primary breast cancer

Fisher

1981

Breast Cancer Res Tr

Self Cite

View full text Add to dashboard Cite

The function of the surgeon remains the same relative to the management of primary breast cancer. What has changed is our perception of the biology of the disease and our understanding of data evaluation and analysis. This presentation provides an overview of some of the more important findings which have altered our understanding of breast cancer and which have led to a reassessment of the basis for cancer surgery. It also emphasizes why controlled clinical trials are necessary for obtaining credible data. To most succinctly summarize the author's position regarding a number of critical controversies related to primary breast cancer surgery, answers are presented to ten of the questions most frequently posed by surgeons regarding surgical therapy.

show abstract